U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C24H23N5O.CH4O3S
Molecular Weight 493.58
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of RIVOCERANIB MESYLATE

SMILES

C1CCC(C1)(C#N)c2ccc(cc2)NC(=O)c3cccnc3NCc4ccncc4.CS(=O)(=O)O

InChI

InChIKey=FYJROXRIVQPKRY-UHFFFAOYSA-N
InChI=1S/C24H23N5O.CH4O3S/c25-17-24(11-1-2-12-24)19-5-7-20(8-6-19)29-23(30)21-4-3-13-27-22(21)28-16-18-9-14-26-15-10-18;1-5(2,3)4/h3-10,13-15H,1-2,11-12,16H2,(H,27,28)(H,29,30);1H3,(H,2,3,4)

HIDE SMILES / InChI

Molecular Formula CH4O3S
Molecular Weight 96.1068
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Molecular Formula C24H23N5O
Molecular Weight 397.4732
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Apatinib is an orally bioavailable, small molecule tyrosine kinase inhibitor that selectively inhibits the vascular endothelial growth factor receptor-2 and used for the treatment of metastatic gastric cancer or gastroesophageal junction cancer that has progressed or relapsed after chemotherapy. To date, second-line ramucirumab and third-line Apatinib are the only anti-angiogenic approaches that have significantly improved the survival of patients with metastatic gastric cancer. Apatinib exhibited potent, highly-selective inhibition of VEGFR-2, c-kit, c-src, and RET tyrosine kinases. The efficacy of Apatinib monotherapy in patients with metastatic gastric cancer or gastroesophageal junction cancer for whom at least two prior chemotherapy regimens had failed was demonstrated in randomized open-label or double-blind phase II trials and a pivotal placebo-controlled phase III trial, all of which were conducted in China. Further clinical experience and long-term pharmacovigilance are required to definitively establish the efficacy and safety profile of Apatinib, including its use in combination with other chemotherapeutic agents.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Target ID: P35968
Gene ID: 3791.0
Gene Symbol: KDR
Target Organism: Homo sapiens (Human)
1.0 nM [IC50]
Substance Class Chemical
Created
by admin
on Sat Jun 26 13:03:29 UTC 2021
Edited
by admin
on Sat Jun 26 13:03:29 UTC 2021
Record UNII
TK02X14ASJ
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
RIVOCERANIB MESYLATE
USAN  
Official Name English
RIVOCERANIB MESYLATE [USAN]
Common Name English
APATINIB MESYLATE
Common Name English
APATINIB MESYLATE [WHO-DD]
Common Name English
YN-968D1
Code English
YN968D1
Code English
3-PYRIDINECARBOXAMIDE, N-(4-(1-CYANOCYCLOPENTYL)PHENYL)-2-((4-PYRIDINYLMETHYL)AMINO)-, METHANESULFONATE (1:1)
Systematic Name English
N-(4-(1-CYANOCYCLOPENTYL)PHENYL)-2-((PYRIDIN-4-YLMETHYL)AMINO)PYRIDINE-3-CARBOXAMIDE MONOMETHANESULFONATE SALT
Systematic Name English
Classification Tree Code System Code
EU-Orphan Drug EU/3/17/1840
Created by admin on Sat Jun 26 13:03:30 UTC 2021 , Edited by admin on Sat Jun 26 13:03:30 UTC 2021
FDA ORPHAN DRUG 579117
Created by admin on Sat Jun 26 13:03:30 UTC 2021 , Edited by admin on Sat Jun 26 13:03:30 UTC 2021
Code System Code Type Description
PUBCHEM
45139106
Created by admin on Sat Jun 26 13:03:30 UTC 2021 , Edited by admin on Sat Jun 26 13:03:30 UTC 2021
PRIMARY
ChEMBL
CHEMBL3186534
Created by admin on Sat Jun 26 13:03:30 UTC 2021 , Edited by admin on Sat Jun 26 13:03:30 UTC 2021
PRIMARY
FDA UNII
TK02X14ASJ
Created by admin on Sat Jun 26 13:03:30 UTC 2021 , Edited by admin on Sat Jun 26 13:03:30 UTC 2021
PRIMARY
WIKIPEDIA
APATINIB
Created by admin on Sat Jun 26 13:03:30 UTC 2021 , Edited by admin on Sat Jun 26 13:03:30 UTC 2021
PRIMARY
EPA CompTox
1218779-75-9
Created by admin on Sat Jun 26 13:03:30 UTC 2021 , Edited by admin on Sat Jun 26 13:03:30 UTC 2021
PRIMARY
NCI_THESAURUS
C74012
Created by admin on Sat Jun 26 13:03:30 UTC 2021 , Edited by admin on Sat Jun 26 13:03:30 UTC 2021
PRIMARY
CAS
1218779-75-9
Created by admin on Sat Jun 26 13:03:30 UTC 2021 , Edited by admin on Sat Jun 26 13:03:30 UTC 2021
PRIMARY
Related Record Type Details
PARENT -> SALT/SOLVATE
Related Record Type Details
ACTIVE MOIETY